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It is well known that the skin is the largest organ in the human 
body. It provides a protective barrier against the environment, has 
a role in immunoprotection, and is an indicator of overall well 
being and health. One’s skin is the outward appearance that one 
displays to the world. For this reason, it can be considered to be an 
organ associated with physical attractiveness and beauty. Albeit 
controversial, in most cultures in the world, beauty is associated 
with youth, and it is desirable to retain youth in professional and 
personal realms. Youth is conveyed through actions and attitude 
and, most importantly, through physical appearance.
Koblenzer has written that the quest for youthful beauty is 
considered a universal fact of life and aging is not considered 
desirable in today’s world.1 Others have posed the question of 
whether antiaging is a scientific concern or a social trend.2 In 
the book Face It, two former models, now psychotherapists, 
argue that, for a woman, dealing with age-associated changes 
in appearance can be as daunting as dealing with financial loss 
or divorce. It is not necessarily about vanity, say the authors, 
but rather about the perceived loss of potential and self-doubts 
about one’s future place in the world.3 Whether or not one buys 
into such a value system, the area of enhancement and pres-
ervation of beauty will continue to grow exponentially in the 
foreseeable future.
Beauty is a subjective notion, yet there are standards that 
seem to remain consistent across cultures and societies. In gen-
eral, beauty is associated with a youthful appearance. Young 
skin is characterized by homogeneous color, smooth texture, 
tautness, dewiness, a lack of irregular pigmented lesions (len-
tigines), and the absence of wrinkles. It is supple to the touch 
and lacks dryness. Aged skin is rough and wrinkled and has 
irregular pigmentation and areas of erythema (telangiectases). 
Such skin may be atrophic or hypertrophic and is dry on palpa-
tion (Figure 1).
The upkeep and maintenance of a youthful appearance have 
become more accessible through the invention and develop-
ment of drugs and devices to reverse the changes seen in aging 
skin. This quest for youth has spawned an enormous industry in 
cosmetic agents and procedures as evidenced by the accelerated 
financial growth in this industry.
Why a particular person looks old or young for his or her age 
is poorly understood. It is likely that a combination of genetically 
inherited factors such as variants in the MC1R gene, hair gray-
ing, and lip height are coupled with extrinsic factors to produce a 
perceived clinical age.4,5 Light-skinned individuals or those with 
Fitzpatrick skin types I and II, defined as skin that burns easily/
never or rarely tans, tend to show premature aging much more 
noticeably than those with Fitzpatrick types IV–VI. Those who 
have had extensive exposure to ultraviolet (UV) light have pre-
maturely aged skin. Darker skin types age more slowly because 
of the protective effects of melanin.
IntrInsIc Vs. ExtrInsIc AgIng
Intrinsic aging, also known as chronological aging or natural 
aging, is clinically manifested as fine wrinkles and a crepe-like 
texture to the skin on sun-protected sites such as the upper 
inner aspect of the arm or on the hip (Figure 2). The skin has an 
atrophic and dry appearance, and the color is generally homo-
geneous without dyspigmentation.
The hallmarks of extrinsic aging or photoaging are wrin-
kles and a rough texture on sun-exposed sites such as the 
1Department of Dermatology, University of Michigan Medical Center, ann arbor, Michigan, USa. Correspondence: DL Sachs (dsachs@med.umich.edu)
Received 15 July 2010; accepted 19 September 2010; advance online publication 24 November 2010. doi:10.1038/clpt.2010.259
age-Reversing Drugs and Devices in 
Dermatology
DL Sachs1 and JJ Voorhees1
The quest for youth and beauty is an ongoing one. No organ conveys youth and beauty to the extent that skin does. 
Advances in research over the past several decades have yielded a tremendous amount of information on the molecular 
pathways involved in both intrinsic aging (natural) and extrinsic aging (photoaging). In this article, we aim to describe the 
molecular pathways that lead to an aged appearance and to describe the latest and most commonly employed drugs and 
procedures to reverse skin aging and stimulate the production of new collagen. With enhanced understanding of these 
molecular pathways, drugs and devices used to treat aging skin can be more precisely tuned.
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face and forearms. UV light is the major driver of extrinsic 
aging, but other factors such as tobacco use may be contribu-
tory. Two clinical phenotypes of extrinsic photoaging have 
been observed. In the more common type, namely, atrophic 
photoaging, the individuals have numerous fine wrinkles on 
the face, epidermal atrophy, telangiectases, and focal depig-
mentation. They also tend to have skin cancers and precan-
cers and typically belong to Fitzpatrick skin type I or II. In 
the less common type, hypertrophic photoaging, individuals 
have deeper, coarser facial wrinkles and lentigines but few 
skin cancers. They tend to have Fitzpatrick type III or IV 
(Figure 3).6,7
Intrinsic and extrinsic aging are superimposed on each other. 
Intrinsic aging is characterized by subtle changes occurring 
over a lifetime, whereas extrinsic aging tends to occur in the 
setting of intrinsic aging and generally accelerates and exag-
gerates the process of intrinsic aging. Extrinsic aging is seen in 
skin of color but to a much lesser extent. In individuals with 
darker skin, extrinsic aging is visible to a much lesser extent, 
with pigmentary changes predominating over textural changes 
(Figure 4).
MolEculAr MEchAnIsMs In AgIng skIn
In recent decades, much work has been done to elucidate the 
molecular mechanisms of aging in skin. A major factor that 
determines the appearance of the skin is the condition of the 
dermal collagen. Although there are differences between young 
and aged skin with respect to the condition of the epidermis, 
dermal collagen is the most important factor in whether the 
skin appears to be young or old. The dermal extracellular 
matrix is composed of type I collagen, proteoglycans, and gly-
cosaminoglycans produced and secreted by fibroblasts. Type I 
collagen is the most abundant protein in the dermal extracel-
lular matrix. It is responsible for the support and structure of 
the skin, and its loss and degradation are thought to result in the 
clinical phenotype of aged skin, specifically with regard to fine 
and coarse wrinkles.8–10 Elastic fibers are another key protein 
in skin and reside in the papillary and reticular dermis. They 
provide elasticity and recoil capacity to skin. Certain diseases of 
elastic fibers, such as Marfan’s syndrome (fibrillin-1 mutation) 
and Williams syndrome (elastin mutations), are characterized 
by loss of elasticity, much like that seen in aged skin. Clearly, loss 
and damage of elastic fibers are contributory to the clinical and 
molecular changes seen in aged skin, but, for practical reasons, 
the majority of the research work being carried out is focused 
on collagen.
Collagen fibers provide “scaffolding” for fibroblasts; this 
scaffolding is critical for the maintenance of the collagen net-
work because it allows the fibroblasts to exist in a “stretched” 
Figure 2 Intrinsic aging. Intrinsic aging, also known as natural aging, is clearly 
demonstrated on the upper inner aspect of the arm. The salient features are 
homogeneous color, atrophy, and fine wrinkling.
Figure 3 Extrinsic aging. Extrinsic aging is also known as photoaging and 
is superimposed on intrinsic aging. Ultraviolet light accounts mainly for 
the changes that are characteristic of this type of aging, although cigarette 
smoking is also a contributory factor. On the left, the more common form of 
photoaging is shown, namely, atrophic photoaging, which is characterized 
by lentigines, patchy erythema, telangiectases, fine wrinkling, and actinic 
keratoses. The hypertrophic variant is seen on the right, with deep, coarse 
wrinkles, and little dyspigmentation or erythema. Fewer actinic keratoses and 
skin cancers are seen in this variant.
Young 
     Clinical                 Histologic 
     Homogeneous color           Organized, intact collagen 
     Smooth texture           “Stretched” fibroblasts 
     Few to no wrinkles 
     Taut 
     Hydrated 
  Old 
     Clinical                 Histologic 
     Dyspigmentation           Decreased collagen 
     Wrinkles                 Fragmented collagen 
          Dynamic            “Collapsed” fibroblasts 
          Fine 
          Coarse 
     Rough texture 
     Dry 
     Patchy erythema 
      
Figure 1 Clinical and histologic features of young skin and old skin.
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configuration, as is typical of young, healthy, non-sun-damaged 
skin.11 The fibroblasts appear elongated, with abundant endo-
plasmic reticulum indicative of the active collagen protein–
producing machinery. Collagen fibrils are intimately associated 
with these elongated fibroblasts and are seen in close proximity 
to them. In contrast, the fibroblasts in old and sun-damaged 
skin exist in a “collapsed” configuration, and the cells appear 
much smaller than the stretched fibroblasts. There is minimal 
endoplasmic reticulum in these fibroblasts as seen by electron 
micrography, indicating that the collagen-producing machin-
ery is minimally productive. In old, sun-damaged skin, collagen 
fibrils are not seen in close proximity external to the fibroblasts 
and are fragmented. The relationship between the fibroblasts and 
the collagen matrix is an interdependent one, with the fibrob-
lasts serving as the structure or anchor for the collagen fibers 
and the collagen fibers allowing the fibroblasts to exist in their 
“stretched” configuration (Figure 5).10
Extrinsic aging is associated with episodic photodamage, 
which culminates in permanent photoaging. Minimal erythema 
dose refers to the amount of UV radiation that causes barely 
perceptible skin reddening. A mere 0.01 minimal erythema 
dose leads to statistically significant injury that will induce the 
molecular sequence of events resulting in collagen deficiency, 
collagenase excess, and micro- and macro-scarring leading to 
solar scars. These additive solar scars are associated with the 
clinical presentation of wrinkles. Both UVB and UVA radiation 
lead to an increase in reactive oxygen species (ROS). Specifically, 
exposure to two minimal erythema doses leads to the production 
of H2O2, which gives rise to other oxygen free radicals within 
a matter of minutes. ROS play an important role in direct cel-
lular damage (cell walls, lipid membranes, mitochondria, and 
DNA) as well as in molecular signaling. Through ROS signaling, 
transforming growth factor-β, a cytokine that promotes collagen 
production, is blocked, and the formation of new collagen is 
reduced. Also mediated through ROS signaling is the epidermal 
growth factor receptor pathway, which signals activator pro-
tein-1, a transcription factor responsible for upregulating colla-
genase, a matrix metalloproteinase that is important in collagen 
breakdown. The upregulation of collagenase leads to an increase 
in collagen fragmentation that in turn leads to a decrease in the 
mechanical tension of the fibroblast. Loss of mechanical tension 
leads to perpetuation of the cycle in which collagenase concen-
tration is increased, leading to further collagen fragmentation 
and, ultimately, permanent collagen loss clinically manifested 
as permanent photoaging. Each UV insult results in solar scars, 
which manifest as a wrinkle8,12,13 (Figure 6).
The sequence of events in intrinsic aging is similar but with a 
few notable exceptions. The damage in natural aging is continu-
ous rather than episodic and is caused by the passage of time 
rather than by UV damage. The increase in ROS signaling leads 
to a decrease in collagen formation mediated by transforming 
growth factor-β, as in extrinsic aging. The increase in collagenase 
level, however, is mediated through the JNK pathway rather than 
through the epidermal growth factor receptor pathway.
The above discussion is focused on collagen in aging skin 
because most of the ongoing research is focused on this vital 
skin protein. There have, however, been findings to suggest that 
there is a difference between photoprotected and photodamaged 
skin with regard to extracellular protein matrix. The extracellular 
matrix is important because of its water-binding capacity. Four 
glycosaminoglycans were identified in skin samples: hyaluronic 
acid (HA), heparan sulfate, dermatan sulfate,14 and chondroitin 
sulfate. In a study of photodamaged facial skin as compared 
with photoprotected postauricular skin used as a control, pho-
toexposed skin was observed to have a significant increase in 
Figure 4 Skin aging in skin of color. In darker skin types, aging skin may be 
characterized more by pigmentary changes than by wrinkles.
Young Old
Stretched FB Collapsed FB
Intact Collagen Fibers Fragmented Collagen Fibers
Figure 5 Electron micrographs (EMs) of young skin and old skin. young 
skin is characterized histologically by intact, organized collagen fibers in the 
dermis. On scanning the EMs, it is seen that the fibroblast is in a “stretched” 
configuration and is in close proximity to collagen fibers. abundant 
endoplasmic reticulum can be visualized in the cytoplasm, indicating active 
protein synthesis. In old skin, collagen is fragmented. The fibroblast structure 
has collapsed, and very little cytoplasm is apparent. The fibroblast has lost its 
connections to the surrounding collagen fibrils.
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the content of HA and DS as compared with photoprotected 
skin. The increase in HA was associated with an increase in the 
amount of fragmented HA, which is abnormal and does not 
interact in the usual manner with water.15
thE solutIon
Medical and procedural interventions are available to improve 
aging skin. Medical interventions typically refer to topical agents 
that will prevent sun damage or stimulate the production of 
new collagen. These treatments are long-term solutions, and the 
results, although measurable, can be subtle and occur over fairly 
long periods of time. Medical treatments focus mainly on the 
issue of abnormal collagen; such treatments include the use of 
topical retinoids, select antioxidants, and, more recently, drugs 
that are used primarily to resolve precancerous skin lesions 
known as actinic keratoses. Medical treatments are usually in 
the form of prescription medications, but some are available as 
over-the-counter preparations.
Procedural treatments, on the other hand, tend to lead 
to more dramatic changes, and the effects are noted sooner 
than with medical therapy alone. These procedures are often 
employed in conjunction with medical therapy to combat the 
effects of aging skin. Procedures such as laser surgery can 
address dyspigmentation, redness, and textural changes. Soft-
tissue fillers address the volume loss associated with aging. 
Botulinum toxin injections are used to treat dynamic wrinkles 
associated with repeated muscle movement and that ultimately 
lead to “fixed” wrinkles at rest. These procedures are adminis-
tered by trained professionals and can be associated with sig-
nificant side effects. Appropriate identification of individuals 
qualified to carry out these procedures is of the utmost impor-
tance (Figure 7).
PhotoProtEctIon
The only reliable way to prevent photoaging is through adequate 
protection against UV radiation from sunlight. Individuals should 
be educated to avoid the strong midday sun and to use sun-
 protective devices such as UV-protective clothing, broad-brimmed 
hats, umbrellas, and sunglasses. It is also strongly recommended 
that the use of artificial sources of UV light (i.e., sunlamps and tan-
ning beds) be avoided because they emit UVA, which is known to 
be associated with premature skin aging and skin cancer.16
Sunscreens are broadly defined as agents that protect 
against UV damage, sunburn, wrinkles, and pigmentary 
























Figure 6 Sequence of events culminating in photoaging. Episodic ultraviolet 
(UV) B and ultraviolet a1 exposure leads to the generation of ROS including 
H2O2. ROS signaling leads to blockade of the TGF-β pathway, and new 
collagen formation is blocked. ROS signaling also induces EGF-R to signal 
aP-1, which upregulates the matrix metalloproteinase collagenase, the major 
enzyme responsible for collagen breakdown. The induction of collagenase 
results in an increase in collagen fragmentation, leading to a breakdown in 
the collagen scaffolding that supports the fibroblast. This loss in mechanical 
tension promotes further increases in collagenase level, resulting in collagen 
fragmentation. Repeated episodes culminate in permanent loss of collagen, 
clinically manifested as wrinkles and laxity of the skin. aP-1, activator 
protein-1; EGF-R, epidermal growth factor receptor; ROS, reactive oxygen 
species; TGF-β; transforming growth factor-β.
Therapy                           Main action 
Medical 
     Sunscreens                 Prevent UV damage 
     Topical retinoids                Repair dermal collagen 
     Antioxidants 
          N-acetylcysteine (NAC) 
          Genistein 
          Vitamin C 
          Idebenone  
     Peptides                      Collagen? 
     5-Fluorouracil                Stimulate wound healing 
     Imiquimod                     Restore epidermal thickness 
Lasers/light based 
     Ablative                       Stimulate wound healing 
          Conventional CO2 
          Erbium:yag 
     Nonablative           
          Vascular                 Resolve telangiectases 
          Q switched             Resolve dyspigmentation                
          Intense-pulsed light           Resolve telangiectases and dyspigmentation 
          Radiofrequency      Heat stimulates collagen production 
     Fractionated 
          CO2                 Stimulate wound healing 
          Fraxel 
 
Injectables 
     Botulinum toxin type A             Dynamic rhytides 
          Onabotulinum toxin 
          Abobotulinum toxin 
     Soft tissue fillers         Restore volume 
          Temporary           
               Bovine collagen 
               Porcine collagen 
               Human collagen 
               CL-HA             Restore volume  
H2O retention 
Increase “stretched” fibroblast state 
          Semipermanent 
               Poly-L-lactic acid 
               Calcium hydroxylapatite 
          Permanent 
               Liquid silicone 
               Polymethylmethacrylate  
suspended in collagen 
 
Miscellaneous 
          Microdermabrasion       Stimulate wound healing 
Figure 7 age-reversing therapies and their main sites of action. CL-Ha, cross-
linked hyaluronic acid.
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recommendations. They are rated in terms of their sun protec-
tion factor (SPF), which is an indicator of how long a person can 
remain in the sun before starting to develop erythema as com-
pared with not using a sunscreen. SPF pertains only to UVB pro-
tection, not UVA protection. The SPF of a sunscreen increases 
the inherent time to sunburn or suntan. SPFs of sunscreens cur-
rently range from 8 to ~60–70. A higher SPF theoretically means 
that a sunscreen requires less frequent application. Sunscreens 
need to be applied frequently and abundantly because, in real-
life situations, they tend to rub and wipe off with moisture from 
sweat and activities involving water.
Sunscreens may consist of physical or chemical blockers. 
Physical blockers work by blocking or reflecting UVA and UVB. 
Examples of physical blockers include titanium dioxide and zinc 
oxide. These agents are associated with a chalky opaque white 
appearance when applied, but newer formulations have improved 
the cosmesis of these agents. Specifically, nanoparticle technology 
has revolutionized drug delivery systems for these sunscreens 
by imparting a light, nongreasy feel to titanium dioxide and zinc 
oxide sunscreens. It also decreases the white, chalky appearance 
and allows these blockers to be spread more evenly over the skin’s 
surface. There has been some concern about long-term risks 
relating to nanoparticle absorption and consequent systemic 
toxicity because nanoparticles have been associated with oxida-
tive stress leading to protein, DNA, and mitochondrial damage 
and inflammation. To date, however, there is no evidence of der-
mal penetration of titanium dioxide and zinc oxide formulated in 
nanoparticles, and no particles have been found in the interfol-
licular epidermal tissue below the stratum corneum.17,18
Chemical sunscreens initially conferred protection only 
against UVB, but recent-generation chemical sunscreens protect 
against both UVB and UVA. Some examples of UVA blockers 
include oxybenzone and avobenzone. Recently, ecamsule, mar-
keted as Mexoryl, received US Food and Drug Administration 
approval, and a daily cream containing ecamsule and avoben-
zone was found to protect against photoaging.19 Properly 
applied sunscreens that protect against UVB and UVA can pre-
vent UV-induced upregulation of matrix metalloproteinases and 
subsequent collagen breakdown (JJ. Voorhees and G. Fisher, 
unpublished data).
Polypodium leucotomos is a chemical extracted from a 
tropical fern that is found in abundance in Central and South 
America. In a study of the oral formulation of this chemical, a 
significant decrease in UV-induced erythema, sunburn cells, 
and cyclobutane pyrimidine dimers was observed, leading to 
the conclusion that it is an effective systemic chemoprotective 
agent for skin against UV radiation.20
rEtInoIds
Retinoids are vitamin A derivatives that have been used in der-
matology over many decades to treat acne, psoriasis, and aging 
skin. The finding that patients being treated for severe acne with 
isotretinoin, an oral retinoid associated with significant birth 
defects, prompted great interest in topical forms of vitamin A for 
cosmetic improvement of aged skin. Despite the abundance of 
topical agents claimed to improve aging skin, there is substantial 
evidence of effectiveness only for topical retinoids. Kligman was 
one of the first to note that tretinoin ameliorates the signs of 
aging skin.21 These drugs are typically applied every night and 
are associated with some irritation and desquamation during 
the early stages of therapy. These side effects tend to lessen with 
time, but, because the treatment involves continued use of the 
drugs, some patients find the side effects unacceptable. Topical 
retinoids have been considered to be phototoxins, but this clas-
sification is probably less clear than was initially thought. Several 
studies have suggested that they are neither phototoxic nor pho-
toallergic in vivo.22 In controlled studies, when skin is pretreated 
with tretinoin and irradiated with UV light, there is no effect 
on the minimal erythema dose, indicating that tretinoin has no 
phototoxic activity and lacks sunscreen properties as well.8
Tretinoin (all-trans-retinoic acid) is a topical vitamin A 
derivative that binds to and activates the nuclear retinoic acid 
receptor RAR; it is derived from sequential oxidation of all-
trans retinol and all-trans retinaldehyde.23 It is available in 
several strengths and formulations in the United States by 
prescription only. It is dispensed in several forms: cream, gel, 
and in microsphere technology as well as in an emollient base. 
Numerous studies with tretinoin have confirmed its antiag-
ing properties. It has been noted to impact several features 
of photoaged skin; surface roughness, dyspigmentation, and 
fine wrinkles are consistently and significantly improved with 
tretinoin therapy.24 The wrinkle improvement feature of this 
drug has generated much interest, including among physicians. 
Within the first week of tretinoin therapy, tactile smoothing of 
the skin is noted, corresponding with the histologic changes 
of compactness of the stratum corneum and spongiosis in the 
epidermis.25,26 Wrinkle improvement is not seen until after 2–4 
months of therapy. It has been noted that despite continued 
treatment with tretinoin the epidermis reverts to its pretreat-
ment state. Therefore, the wrinkle improvement is attributed 
to dermal changes rather than epidermal ones.27,28 The dermal 
changes resulting from tretinoin therapy are significant and well 
reported. As discussed earlier, type I collagen is the major struc-
tural protein of the dermis, and it is reduced and fragmented in 
aged skin. In an open-label study of treatment with tretinoin 
0.05% cream to facial skin for a minimum of 6 months, the drug 
was demonstrated to thicken the collagen band in the papil-
lary dermis.29 In a 16-week, double-blind, vehicle-controlled 
study of 30 subjects with photoaged forearms and facial skin, 
there was significant improvement in photodamaged skin as 
measured in relation to clinical and histological end points.25 
A landmark study of topical tretinoin applied to sun-damaged 
forearm skin and sun-protected buttock skin demonstrated sig-
nificantly less collagen type I formation at sun-damaged sites 
as compared with sun-protected sites. Treatment of the sun-
damaged sites for 10–12 months with topical tretinoin led to an 
80% increase in extracellular collagen I staining as compared 
with vehicle-treated skin, which showed a 14% reduction in 
collagen I staining (Figure 8).30
Retinol, retinol derivatives, tazarotene, and adapalene for 
aging skin are discussed in detail in the Supplementary Data 
online.
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EstrogEn
The effects of estrogen on skin and changes seen in menopause 
are discussed in the Supplementary Data online.
A recent study evaluated the effectiveness of topical estradiol 
in stimulating production of collagen I and III in naturally aged 
and photoaged skin in postmenopausal women and age-matched 
men. The subjects underwent a 2-week topical application of var-
ious strengths of estradiol or vehicle to photoaged or naturally 
aged skin, and biopsies were performed after the treatment. In 
this study, collagen production in women was seen to be stimu-
lated in sun-protected skin only. This effect was also observed 
in sun-protected skin of the male controls but to a lesser degree. 
Photoaged skin of the forearms in both women and men showed 
no increase in collagen production with this regimen.31
AntIoxIdAnts
Antioxidants are natural or synthetic agents that protect cells 
from damage and scavenge free radicals. As discussed earlier, 
ROS play critical roles in skin-aging pathways, and targeting 
them is an attractive therapeutic consideration. Much interest 
has been generated in these compounds for the treatment of 
aging skin.32 In general, oral supplementation with antioxidants 
has not been shown to be effective in improving photoaged skin. 
There are many pitfalls in carrying out this type of research 
activity. The designing of antioxidant trials involves identifying 
appropriate candidate agents, determining dosing schedules and 
duration of therapy, and allowing for potential side effects such 
as toxicity and drug interactions.
A few antioxidant compounds have drawn more attention 
than others; these include N-acetylcysteine, genistein, vitamin 
C, and the synthetic coenzyme Q10, known as idebenone. A 
discussion about the important studies with these antioxidants 
can be found in the Supplementary Data online.
PEPtIdEs
Peptides are amino acid chains that are fragments of large 
proteins such as collagen. There is evidence in wound-healing 
models that certain peptides penetrate into the dermis and 
stimulate the production of collagen. Because of this property, 
there is interest in using peptides in topical antiaging therapies. 
One such peptide, Pal-KTTS, marketed as Matrixyl (Sederna, 
France), is an ingredient in a number of cosmeceuticals. It pro-
motes a youthful appearance of the skin and has been shown to 
stimulate collagen production in wounds.33 Another peptide 
used in cosmeceuticals is a tripeptide–copper complex (GHK–
copper peptide) that has been shown to increase collagen levels 
in wounds.34 However, none of the peptide-containing agents 
has been rigorously evaluated by means of double-blinded, 
vehicle-controlled studies for their effects on aging skin.
5-FluorourAcIl
Topical 5-fluorouracil (5-FU) has been used since the 1960s to 
treat actinic keratoses and certain superficial nonmelanoma skin 
cancers. Early findings were that patients treated with topical 
5-FU had a more youthful appearance to their skin and that 
wrinkles were reduced after treatment,35 leading to an excel-
lent cosmetic and therapeutic result. In recent work on the use 
of topical 5-FU in the treatment of actinic keratoses and pho-
toaging, these early observations were confirmed by means of 
molecular measurements. In a study of 21 subjects with moder-
ate to severe photoaging and actinic keratoses, topical 5-FU was 
applied twice daily for 2 weeks in accordance with the manu-
facturer’s recommendations. Skin biopsies were performed at 
baseline, immediately after the last application of 5-FU, and at 
several points over a 6-month period. Gene expression of the 
effectors of epidermal injury, inflammation, and extracellular 
matrix degradation was significantly increased. Levels of type 
I procollagen mRNA and protein were significantly increased 
at weeks 4 and 24, respectively. After a course of topical 5-FU, 
the predicted series of events associated with wound healing 
occurred. This suggests that even minor epidermal perturba-
tion can lead to statistically significant clinical and molecular 
improvement in aged skin. The severity of wrinkles, dyspig-
mentation, and overall global photoaging, as well as of actinic 
keratoses, was reduced by week 24.36 For patients unwilling to 
undergo costly laser resurfacing procedures and for those with 
actinic keratoses, topical 5-FU can be considered part of the 
antiaging armamentarium.
IMIquIMod
Imiquimod 5% cream is a topical immune modulator approved 
by the US Food and Drug Administration for the treatment 
of genital warts, superficial basal cell carcinoma, and actinic 
keratoses. A few small studies have examined the antiaging 
properties of imiquimod. In one study, 10 women with moder-
ate facial photodamage but without actinic keratoses applied 
imiquimod cream 5 times a week for 4 weeks. Global clinical 
assessments by a dermatologist and by the subjects themselves 
revealed that imiquimod led to wrinkle reduction and improve-
ment in dyspigmentation. The epidermal changes characteristic 
of aging skin were diminished after therapy, notably atrophy 
and atypia; however, dermal changes were not observed in this 
short study.37 In another study, pre- and post-treatment biopsy 
specimens were examined for the histologic changes associated 
Figure 8 Tretinoin therapy for photoaging. after a course of tretinoin 
0.05%, signs of photoaging are reduced. The subject has clinically significant 
reduction in lentigines and wrinkling, and the skin has a smoother and 
younger appearance after the treatment.
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with daily imiquimod therapy for 3 months for lentigo maligna. 
Significant improvements were noted in papillary dermal fibro-
plasia and melanization. Epidermal thickness was restored to 
normal following therapy.38
AblAtIVE lAsEr rEsurFAcIng
For many years, laser procedures have been used to reverse sun 
damage and enhance the condition and appearance of aged skin. 
The use of lasers is based on the principles of selective photother-
molysis. This concept was put forth by Anderson and Parrish in 
1983 and proposes that thermal tissue injury is selective to laser 
light generated with pulsed lasers.39 Ablative laser resurfacing 
refers to procedures that remove skin in a controlled manner, 
leading to wound healing and a subsequent improved appear-
ance of the skin. Descriptions of the molecular changes seen in 
the skin after CO2 laser ablation and of the use of the Er:YAG 
laser are available in the Supplementary Data online.
Ablative laser resurfacing is especially useful for improv-
ing fine facial rhytides of the perioral and periorbital regions. 
Coarser wrinkles are reduced but, typically, not eradicated. The 
tightening effect does not seem to significantly improve dynamic 
rhytides. Ablative resurfacing is associated with a recovery time 
on the order of 2 weeks for skin re-epithelialization, with discom-
fort requiring sedation, and with the potential for scarring. Also, 
the method cannot be used to resurface medium and darker skin 
types because of the risk of hypopigmentation or even hyper-
pigmentation. Post-procedure erythema can persist for weeks to 
months after resurfacing. Vigilant post-procedure wound care 
is needed to ensure proper re-epithelialization. Typically, anti-
virals and antibiotics are prophylactically prescribed given the 
increased susceptibility to herpes simplex virus and bacterial 
infections during the period immediately after laser treatment. 
Isotretinoin therapy within the previous 12 months is a con-
traindication to laser resurfacing of any type.
nonAblAtIVE lAsEr rEjuVEnAtIon
Nonablative techniques to improve the skin’s appearance include 
light sources to (i) target dermal remodeling, (ii) alleviate ery-
thema and telangiectases associated with aged skin, (iii) reduce 
dyspigmentation, and (iv) reduce textural irregularities associ-
ated with rhytides. Because of the side effects and the consider-
able recovery time associated with ablative laser resurfacing, 
there has been tremendous interest in recent years in develop-
ing lasers that use nonablative techniques to stimulate dermal 
collagen to induce remodeling. These lasers are typically in the 
mid- to longer infrared wavelengths. The 1,320-nm Nd:YAG is 
the prototype of a nonablative laser system and is considered a 
mid-infrared laser along with the 1,450-nm diode and 1,540-nm 
Er:glass lasers. In several studies with the 1,320-nm Nd:YAG 
laser, neocollagenesis was noted at 6 months after the treat-
ment, along with minimal to mild improvement with respect to 
rhytides and scars.40,41 Using a single treatment to photoaged 
forearm skin with either the 585-nm pulsed dye laser (PDL) or 
the 1,320-nm Nd:YAG, Orringer et al. were able to demonstrate 
statistically significant increases in type I procollagen mRNA 
expression of 47% (P < 0.05) and 84% (P < 0.05) above baseline 
for the two laser treatments, respectively. Although forearm skin 
was treated rather than facial skin, and it was a single treatment 
rather than serial treatments as would be performed in real life, 
quantifiable changes were seen.42 It is not generally believed, 
however, that the changes resulting from nonablative techniques 
are similar to those seen with ablative laser resurfacing.
Light sources that target erythema and vessels include the 
532-nm potassium titanyl phosphate laser and the 585- or 
595-nm PDLs. The 532-nm potassium titanyl phosphate laser is 
especially useful for the treatment of facial telangiectases that are 
clinically visible. PDLs demonstrate the most significant reduc-
tion in facial erythema and superficial vascular lesions such as 
spider angiomas. PDLs can be adjusted to purpuric or non-
purpuric settings. The purpuric settings typically yield slightly 
better results in treating facial erythema, but this treatment is 
associated with a recovery period of ~2 weeks. In addition to 
the increase in type I procollagen mRNA expression shown in 
the study discussed earlier, PDL treatment was also reported 
to result in a reduction in rhytides, with histologic evidence of 
collagen remodeling and increased cellularity.43
Q-switched lasers, intense pulsed light, and radiofrequency for 
the treatment of aging skin are discussed in the Supplementary 
Data online.
FrActIonAl rEsurFAcIng
Fractional resurfacing, or fractional photothermolysis, describes 
the technology in which only a portion of skin is thermally altered, 
leaving normal, untreated skin surrounding the treated zone.44 
In fractional resurfacing, microthermal treatment zones are 
produced, representing columns of thermally injured skin. This 
technique was designed with the idea of ensuring greater safety 
throughout the laser resurfacing procedure. Both ablative and 
nonablative fractional resurfacing systems are available. Ablative 
fractional systems target water in the epidermis and the dermis 
and create wounds that heal over a period of ~ 1 week. Ablative 
fractional systems include CO2 (10,600 nm), yttrium scandium 
gallium garnet (YSGG) (2,790 nm), and erbium-doped yttrium 
aluminum garnet (2,940 nm). The indications for ablative frac-
tional resurfacing are the same as for traditional ablative resurfac-
ing: rhytides, photodamage, and acne scarring. As compared with 
traditional ablative resurfacing, ablative fractional resurfacing is 
associated with a shorter recovery period with less discomfort for 
the patient because the surface area that is thermally damaged 
is smaller than the area involved in conventional resurfacing. 
Patients undergoing fractional resurfacing experience less ooz-
ing, crusting, edema, and erythema, although scarring has been 
reported in more aggressive settings.45 The reduction in rhytides 
and photodamage is less impressive than with traditional ablative 
resurfacing but is nevertheless considered quite good, given the 
briefer and more comfortable recovery period.
Nonablative fractional systems also target tissue water 
but without ablation. Examples of these systems include 
850–1,350-nm infrared, 915-nm radiofrequency, 1,440-nm 
neodymium-doped yttrium aluminum garnet lasers, and 
1,550-nm erbium lasers. Nonablative fractional lasers are used 
to treat periorbital rhytides, textural problems associated with 
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photodamage, acne scarring, and melasma. With nonablative 
fractional systems, serial treatments are required at 2- to 4-week 
intervals. The risks of nonablative fractional rejuvenation of the 
skin are low with respect to permanent scarring. Patients should 
be cautioned to expect redness, swelling, and a “gritty” feeling to 
the skin that lasts for up to 1 week. Darker-skinned individuals 
with Fitzpatrick skin types III–V may experience some degree 
of hypopigmentation and should be cautioned about this side 
effect.
MIcrodErMAbrAsIon
Microdermabrasion is a technique performed by physicians, 
nurses, and estheticians that is used for very superficial skin 
resurfacing. It has been touted to be useful in reducing acne, 
scars, and wrinkles and is considered a minimally invasive 
procedure with very little associated risk. Microdermabrasion 
systems differ based on the source of the abrasive component. 
Inert crystals such as aluminum oxide or sodium chloride are 
propelled at the skin through a handpiece; this is the most popu-
lar type of system. These are closed-loop systems consisting of a 
receptacle of unused crystals attached to a source of compressed 
air that propels crystals through a tubing and then through a 
disposable or sterilizable handpiece. Such a system is designed to 
prevent cross-contamination between patients. Another system 
employs a handpiece that is embedded with an abrasive stimu-
lus, such as diamond fragments, that contacts the skin directly 
and produces mechanical dermabrasion.
There have been only a handful of studies examining the effi-
cacy of microdermabrasion for wrinkle reduction. There is some 
evidence that microdermabrasion works to improve wrinkles and 
skin texture. In one study, subjects who underwent weekly facial 
microdermabrasion treatments every 8 weeks reported improve-
ment in skin texture. Review of pre- and post-treatment facial 
photographs did not demonstrate improvement when evaluated 
by medical professionals, but lay observers noted reduction in 
fine wrinkles. Biopsies performed after 8 weeks demonstrated a 
thickening of the epidermis, with an increase in collagen content 
as evidenced by Masson’s trichrome staining test.46 In another 
study, subjects noted reduction in textural irregularities, rough-
ness, and mottled pigmentation but did not notice any change 
with regard to wrinkles.47 More rigorous studies of the technique 
were performed by Karimipour et al., who studied the effects of 
a single aluminum oxide microdermabrasion treatment on sun-
protected skin on the buttock and found that there was a statisti-
cally significant elevation in the levels of molecules that regulate 
matrix metalloproteinases that degrade collagen. Importantly, 
and interestingly, there was minimal disruption of the stratum 
corneum, suggesting that significant dermal changes can be seen 
in the absence of epidermal interruption. Specifically, concen-
trations of the proinflammatory transcription factor activator 
protein-1 and cytokines interleukin-1β and tumor necrosis 
factor-α were elevated. The elevation in levels of matrix metal-
loproteinases allows the removal of damaged collagen and the 
placement of new collagen. In this study, 20% of the subjects had 
an increase in type I collagen production as evidenced by immu-
nohistochemical staining.48 In a study involving photodamaged 
forearms, Karimipour et al. used a diamond-studded handpiece 
with varying degrees of abrasiveness and demonstrated that the 
coarse-grit, rather than medium-grit, handpiece was associated 
with rapid induction of cytokeratin 16 and activation of activator 
protein-1. Dermal remodeling was noted to follow this wound-
healing response, highlighted by induction of types I and III 
procollagen.49
soFt-tIssuE InjEctAblEs
Dermal fillers improve the appearance of the skin with respect to 
lines, wrinkles, and certain types of scars by “filling in” areas that 
have experienced loss of collagen and structure. This is the sec-
ond most commonly performed cosmetic procedure, botulinum 
toxin injection being the most common. Typically, dermal fillers 
are injected into the lower two-thirds of the face; the most com-
mon sites are the nasolabial creases. Other commonly injected 
sites that show improvement with this treatment include the 
“marionette lines,” or lines between the angles of the mouth, 
the chin, and the tear troughs. Deficiency in lip volume can be 
corrected with these fillers. The prejowl sulcus, between the chin 
and the mandible, is often a site of volume loss, which can be 
satisfactorily corrected with soft-tissue fillers.
The procedure for administering soft-tissue injections typi-
cally involves a topical anesthetic or regional nerve blocks. 
Injections of the agents are performed using either a serial 
puncture technique or a linear fanning technique. Temporary 
swelling and bruising may result, especially when patients are 
taking blood thinners such as aspirin, nonsteroidal anti-inflam-
matory drugs, warfarin, and vitamin E. The many agents that are 
available for use as dermal fillers can be categorized as tempo-
rary, semipermanent, and permanent fillers. Temporary fillers 
include bovine collagen (Zyderm and Zyplast), porcine collagen 
(Evolence), and human collagen (Cosmoderm and Cosmoplast) 
as well as crosslinked HA fillers (Perlane, Restylane, Juvederm). 
Semipermanent fillers include poly-l-lactic acid (Sculptra) and 
calcium hydroxylapatite (Radiesse). Permanent fillers include 
liquid silicone and polymethylmethacrylate suspended in col-
lagen (Artecoll).
HA fillers are the most popular; they are widely available in 
several variations, each distinguished by its crosslinking proper-
ties. HA is an endogenous polysaccharide that binds water and 
imparts turgor to the skin. When injected into the skin in its 
native form, it hydrolyzes rapidly. With crosslinking, however, 
it is stabilized and degrades at a much slower rate in the dermis. 
HA fillers are derived from bacteria and rooster combs, and gen-
erally last for 4–5 months. “NASHA” is a term used to describe 
the nonanimal stabilized form of HA.
Anecdotally, physicians have observed that injecting colla-
gen and HA fillers repeatedly leads to patients requiring less of 
the product over time. Perhaps the effect of such agents goes 
beyond a mere “filling” effect. Recent work has suggested that 
the mechanism of action of HA fillers extends well beyond their 
space-filling properties.
In a study of 11 subjects with photodamaged forearm skin, 
HA filler was injected into one forearm and saline vehicle into 
the other forearm. Biopsies were taken at 4 and 13 weeks, and it 
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was found that the increase in the level of type I procollagen pro-
tein at the HA-injected site was >90-fold higher than that at the 
saline-injected site. Electron microscopy of the HA-injected sites 
demonstrated the fibroblast to be in a “stretched” configuration 
and the endoplasmic reticulum to be in an activated state, imply-
ing that the collagen-producing machinery of the fibroblast was 
active. The saline-injected site showed the fibroblast remaining 
in its collapsed state, with minimal evidence of the endoplasmic 
reticulum being activated, as in baseline sun damage.50
The mechanism of action of HA fillers is multifactorial and 
includes mechanical filling of the space, water binding (due 
to inherent properties of the polysaccharide), preservation of 
mature collagen (by decreasing the production of collagenase), 
and an increase in production of new collagen (by means of 
mechanical tension on the fibroblast).
botulInuM toxIn
Dynamic wrinkles result from overactive movements of under-
lying muscles leading to skin creases; these are fairly easily cor-
rected with botulinum toxin type A. This has become the most 
common cosmetic procedure in the United States, and extensive 
clinical experience confirms that it is both safe and effective.51 
Dynamic wrinkles are typically seen in the top third of the face, 
particularly in the glabellar complex, the forehead, and the lat-
eral periorbital sites. The skin at these sites becomes creased 
because of repeated contraction of the muscle. Another site that 
is prone to dynamic wrinkles is the perioral region.
The US Food and Drug Administration has approved 
Clostridium botulinum toxin type A injections for cosmetic treat-
ment of glabellar rhytides. Two versions of botulinum toxin type 
A have been approved by the agency: onabotulinum toxin (Botox) 
and abobotulinum toxin (Dysport). The dosing schedules of the 
two products are different. The neurotoxin—a purified protein 
derived from botulinum—works by inhibiting the neurotrans-
mitter acetylcholine at the neuromuscular junction. The heavy 
chain of the protein binds the toxin to the presynaptic cholinergic 
nerve terminal. The light chain cleaves SNAP25, which prevents 
vesicles from fusing with the membrane and prevents the release 
of acetylcholine into the neuromuscular junction. Collateral 
sprouting of new nerve terminals over time leads to restoration 
of function. When injected into the glabellar complex, which 
consists of the procerus and corrugator muscles, the treatment 
paralyzes these dynamic wrinkles or “frown” lines. Repeated 
injections lead to softening and smoothing of the lines at rest. 
The injections are also used for dynamic rhytides of the forehead 
(frontalis) muscles, as well as for those in the lateral periorbital 
regions (orbicularis oculi), commonly known as “crow’s feet.” 
Other common uses of the neurotoxin include treatment of the 
orbicularis oris in very small doses to reduce perioral rhytides 
and injection into the mental crease and platysmal bands.
The injections are associated with temporary discomfort and 
potential bruising, if some of the small facial blood vessels are 
inadvertently injected. This is especially true in patients taking 
aspirin, nonsteroidal anti-inflammatories such as ibuprofen, and 
certain over-the-counter vitamins such as vitamin E, which can 
lead to an increase in bleeding time. Inadvertent injection of 
botulinum toxin into the region of the mid-pupillary line can 
lead to eyelid ptosis; typically, this resolves within a few weeks. 
The duration of the beneficial effect of botulinum toxin injec-
tions is ~4 months.
suMMAry
Our understanding of skin aging, both natural aging and photo-
aging, has advanced significantly over the past several decades. 
The desire to maintain a youthful appearance is pervasive in our 
society, and the demand for medical and procedural treatments 
to achieve a youthful appearance continues to increase. With 
better understanding of the molecular events culminating in 
the breakdown and repair of collagen, it is hoped that newer 
and more sophisticated therapies will be developed for its repair 
and restoration. There are undesirable side effects and economic 
costs associated with the treatments, both medical and proce-
dural, that limit their widespread use.
suPPlEMEntAry MAtErIAl is linked to the online version of the paper at 
http://www.nature.com/cpt
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